FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313430167> ?p ?o ?g. }

• W4313430167 endingPage "64.18" @default.
• W4313430167 startingPage "64.18" @default.
• W4313430167 abstract "Abstract Strain 68-1 rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency virus (SIV) antigens demonstrate a vaccine efficacy where 50–60% of vaccinated rhesus macaques are protected from SIV challenge. Intriguingly, RhCMV/SIV vectors elicit CD8+ T cells recognizing epitopes presented by MHC-II and MHC-E instead of MHC-Ia. We are studying how these unconventional T cell responses are elicited and contribute to the efficacy against SIV challenge. Here we utilize host microRNA (miRNA)-mediated vector tropism restriction to show that MHC-II- and MHC-E-restricted responses are primed by directly infected, non-overlapping cell types in rhesus macaques. Targeting essential RhCMV genes with myeloid cell-selective miR-142-3p eliminated MHC-E-restricted CD8+ T cell priming, yielding an exclusively MHC-II-restricted response, whereas endothelial cell-selective miR-126-3p targeting eliminated MHC-II-restricted CD8+ T cell priming, yielding an exclusively MHC-E-restricted response. Incorporation of both restriction elements reverts CD8+ T cell responses back to conventional MHC-Ia restriction. Using these otherwise isogenic vectors we show that although they demonstrate similar overall immunogenicity, only the vectors programmed to elicit MHC-E-restricted CD8+ T cell responses provided protection against SIV challenge. The MHC-E-only RhCMV/SIV vaccine efficacy did not exceed that of the parental 68-1 RhCMV/SIV vectors (that elicits both MHC-II and MHC-E responses) indicating that while the MHC-II-restricted CD8+ T cell responses are neutral to overall vaccine efficacy, an additional component of 68-1 RhCMV/SIV-induced immunity contributes to overall vaccine efficacy. This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) grants UM1 AI124377 and U19 AI128741 to LJP; the Oregon National Primate Research Center Core grant from the National Institutes of Health, Office of the Director (P51 OD011092); contracts from the National Cancer Institute (# HHSN261200800001E) to JDL; and the Bill and Melinda Gates Foundation grant OPP1107409." @default.
• W4313430167 created "2023-01-06" @default.
• W4313430167 creator A5002966366 @default.
• W4313430167 creator A5003090117 @default.
• W4313430167 creator A5006894592 @default.
• W4313430167 creator A5008024387 @default.
• W4313430167 creator A5011750490 @default.
• W4313430167 creator A5024027617 @default.
• W4313430167 creator A5025855769 @default.
• W4313430167 creator A5025936834 @default.
• W4313430167 creator A5026535321 @default.
• W4313430167 creator A5030877009 @default.
• W4313430167 creator A5031015644 @default.
• W4313430167 creator A5040434996 @default.
• W4313430167 creator A5042263480 @default.
• W4313430167 creator A5043225490 @default.
• W4313430167 creator A5052224057 @default.
• W4313430167 creator A5053992679 @default.
• W4313430167 creator A5055004524 @default.
• W4313430167 creator A5057532500 @default.
• W4313430167 creator A5059051358 @default.
• W4313430167 creator A5059723156 @default.
• W4313430167 creator A5065481449 @default.
• W4313430167 creator A5067574499 @default.
• W4313430167 creator A5080516268 @default.
• W4313430167 creator A5084773223 @default.
• W4313430167 creator A5088424217 @default.
• W4313430167 creator A5088595140 @default.
• W4313430167 creator A5088648154 @default.
• W4313430167 creator A5091630895 @default.
• W4313430167 date "2022-05-01" @default.
• W4313430167 modified "2023-10-16" @default.
• W4313430167 title "RhCMV/SIV tropism modulation programs unconventional CD8+ T cell priming and vaccine efficacy" @default.
• W4313430167 doi "https://doi.org/10.4049/jimmunol.208.supp.64.18" @default.
• W4313430167 hasPublicationYear "2022" @default.
• W4313430167 type Work @default.
• W4313430167 citedByCount "0" @default.
• W4313430167 crossrefType "journal-article" @default.
• W4313430167 hasAuthorship W4313430167A5002966366 @default.
• W4313430167 hasAuthorship W4313430167A5003090117 @default.
• W4313430167 hasAuthorship W4313430167A5006894592 @default.
• W4313430167 hasAuthorship W4313430167A5008024387 @default.
• W4313430167 hasAuthorship W4313430167A5011750490 @default.
• W4313430167 hasAuthorship W4313430167A5024027617 @default.
• W4313430167 hasAuthorship W4313430167A5025855769 @default.
• W4313430167 hasAuthorship W4313430167A5025936834 @default.
• W4313430167 hasAuthorship W4313430167A5026535321 @default.
• W4313430167 hasAuthorship W4313430167A5030877009 @default.
• W4313430167 hasAuthorship W4313430167A5031015644 @default.
• W4313430167 hasAuthorship W4313430167A5040434996 @default.
• W4313430167 hasAuthorship W4313430167A5042263480 @default.
• W4313430167 hasAuthorship W4313430167A5043225490 @default.
• W4313430167 hasAuthorship W4313430167A5052224057 @default.
• W4313430167 hasAuthorship W4313430167A5053992679 @default.
• W4313430167 hasAuthorship W4313430167A5055004524 @default.
• W4313430167 hasAuthorship W4313430167A5057532500 @default.
• W4313430167 hasAuthorship W4313430167A5059051358 @default.
• W4313430167 hasAuthorship W4313430167A5059723156 @default.
• W4313430167 hasAuthorship W4313430167A5065481449 @default.
• W4313430167 hasAuthorship W4313430167A5067574499 @default.
• W4313430167 hasAuthorship W4313430167A5080516268 @default.
• W4313430167 hasAuthorship W4313430167A5084773223 @default.
• W4313430167 hasAuthorship W4313430167A5088424217 @default.
• W4313430167 hasAuthorship W4313430167A5088595140 @default.
• W4313430167 hasAuthorship W4313430167A5088648154 @default.
• W4313430167 hasAuthorship W4313430167A5091630895 @default.
• W4313430167 hasConcept C100701293 @default.
• W4313430167 hasConcept C154317977 @default.
• W4313430167 hasConcept C159047783 @default.
• W4313430167 hasConcept C167672396 @default.
• W4313430167 hasConcept C170627219 @default.
• W4313430167 hasConcept C197695756 @default.
• W4313430167 hasConcept C202751555 @default.
• W4313430167 hasConcept C203014093 @default.
• W4313430167 hasConcept C207936829 @default.
• W4313430167 hasConcept C2522874641 @default.
• W4313430167 hasConcept C2776090121 @default.
• W4313430167 hasConcept C2777995582 @default.
• W4313430167 hasConcept C2780868878 @default.
• W4313430167 hasConcept C54355233 @default.
• W4313430167 hasConcept C59822182 @default.
• W4313430167 hasConcept C81444415 @default.
• W4313430167 hasConcept C86803240 @default.
• W4313430167 hasConcept C8891405 @default.
• W4313430167 hasConceptScore W4313430167C100701293 @default.
• W4313430167 hasConceptScore W4313430167C154317977 @default.
• W4313430167 hasConceptScore W4313430167C159047783 @default.
• W4313430167 hasConceptScore W4313430167C167672396 @default.
• W4313430167 hasConceptScore W4313430167C170627219 @default.
• W4313430167 hasConceptScore W4313430167C197695756 @default.
• W4313430167 hasConceptScore W4313430167C202751555 @default.
• W4313430167 hasConceptScore W4313430167C203014093 @default.
• W4313430167 hasConceptScore W4313430167C207936829 @default.
• W4313430167 hasConceptScore W4313430167C2522874641 @default.
• W4313430167 hasConceptScore W4313430167C2776090121 @default.
• W4313430167 hasConceptScore W4313430167C2777995582 @default.
• W4313430167 hasConceptScore W4313430167C2780868878 @default.
• W4313430167 hasConceptScore W4313430167C54355233 @default.

• next